biotechpeptides.com retatrutide GLP-3 R 10mg Retatrutide | Research Grade Peptide

Perfect for athletes and recovery optimization

In TRIUMPH-2, discontinuation due to adverse events ranged from 3.8% to 11.6% across retatrutide dose groups compared with 4.9% for placebo

In the literature, Retatrutide has been investigated in relation to: body-weight regulation and appetite signalling glucose metabolism and glycaemic markers energy expenditure and substrate utilisation multi-pathway incretin research next-generation obesity and metabolic-disease models For researchers comparing newer metabolic peptides, Retatrutide is often discussed alongside Semaglutide and Tirzepatide because it extends beyond GLP-1/GIP into triple-pathway metabolic modulation

One vial covers 2-5 weeks depending on target weekly dose